Immunogenic composition
AssigneeGlaxosmithkline Biologicals SA
InventorsRalph Leon Biemans, Dominique Boutriau, Carine Capiau, Philippe Denoel, Pierre Duvivier, Jan Poolman
Life of this patent
Estimating the term…
Abstract
The present application discloses an immunogenic composition comprising N. meningitidis capsular polysaccharides from at least one of serogroups A, C, W135 and Y conjugated to a carrier protein to produce a N. meningitidis capsular polysaccharide conjugate, wherein the average size of each N. meningitidis polysaccharide is above 50 kDa.
Claims5
A method of immunizing a human host against disease caused by Neisseria meningitidis infection, comprising administering to the host an immunoprotective dose of an immunogenic composition comprising:
- a stabilizing agent;
- and lyophilized N. meningitidis capsular polysaccharides from serogroups A, C, W, and Y, wherein:
- the serogroup A capsular polysaccharide has an average size of 300 kDa;
- the serogroup C capsular polysaccharide has an average size of 200 kDa;
- the serogroup Y capsular polysaccharide has an average size of 101-300 kDa;
- the serogroup W capsular polysaccharide has an average size of 101-300 kDa;
- and
- wherein each N. meningitidis capsular polysaccharide is a N. meningitidis capsular polysaccharide conjugate comprising a N. meningitidis capsular polysaccharide conjugated to a tetanus toxoid carrier protein,
- wherein the immunogenic composition elicits in the host an immune response which comprises an antibody titer against MenA, MenC, MenW, and Men Y greater than 0.3 μg/ml.
Dependencies are inferred from the claim text.